摘要 |
PCT No. PCT/SE94/00297 Sec. 371 Date Dec. 21, 1995 Sec. 102(e) Date Dec. 21, 1995 PCT Filed Mar. 31, 1994 PCT Pub. No. WO95/01804 PCT Pub. Date Jan. 19, 1995A pharmaceutical formulation for subcutaneous, intramuscular or intradermal administration comprising recombinant coagulation factor VIII and use thereof for manufacture of a medicament for treating haemophilia is provided. The formulation comprises a highly purified recombinant coagulation factor VIII in a concentration of at least 1000 IU/ml, which gives surprisingly high levels of active factor VIII in the blood stream after subcutaneous, intramuscular or intradermal administration. The formulation is intended for treatment of haemophilia by subcutaneous, intramuscular or intradermal administration. The recombinant factor VIII is preferably a deletion derivative thereof, which can be used for the manufacture of a medicament for subcutaneous administration. |